A new analysis presented at the American Society of Hematology Annual Meeting suggests that omitting 24-hour urine testing from multiple myeloma response assessments does not compromise accurate tracking of patients’ responses to treatment. Evaluating patients’ responses using urine-free and traditional criteria led to nearly identical assessments in the study of 645 patients. The findings support dropping routine urine tests from International Myeloma Working Group response criteria, which are currently recommended but are cumbersome for patients and can lead to disparities. The study showed that urine-free response criteria were just as effective as traditional criteria, with only a small number of patients having discordant results.
Source link
24-Hour Urine Testing in Multiple Myeloma: Time to Stop?
